Actuate Therapeutics (ACTU) Stock Price, Quote, News & History | Benzinga

Actuate Therapeutics Inc (ACTU) Stock Price, Quote, News & History

ACTUNASDAQ

Trade with Public

Trade with Public

$1.27

0.043.25%

At close: Aug 21, 5:00 PM EST

$1.29

0.021.57%

After Hours: 6:34 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.22

Close

$1.27

Volume / Avg.

275.82K / 275.23K

Day Range

$1.18 - $1.34

52 Wk Range

0.90 - 9.22

Market Cap

$30.98M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

4.26%

Days to Cover

2.9

Recent Actuate Therapeutics Inc News

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.

Avi Kapoor

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.

Mohd Haider

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.

Avi Kapoor

Partner Content

Actuate Therapeutics: Poised For Potential $200M+ Pediatric Priority Review Vouchers And Transformative Combinations In RAS-Driven Cancers

This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-19.84M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

17.77M

Free Cash Flow (TTM)

-19.84M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-2.07M

Analyst Trends and Forecast

2

Apr

1

May

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$37.05M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

29.86

Earnings Yield % (TTM)

-70.73%

Earnings Yield % (FWD)

-60.16%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.04

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$4.43M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.22

Close

$1.27

Volume / Avg.

275.82K / 275.23K

Day Range

$1.18 - $1.34

52 Wk Range

0.90 - 9.22

Market Cap

$30.98M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

4.26%

Days to Cover

2.9

About

Sector

Health Care

Industry

Biotechnology

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Actuate Therapeutics (ACTU) stock?

A

You can purchase shares of Actuate Therapeutics (NASDAQ:ACTU) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Actuate Therapeutics (ACTU) competitors?

A

Other companies in Actuate Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Actuate Therapeutics (ACTU) stock?

A

Actuate Therapeutics has a consensus price target of $13.67.

Q

What is the current price for Actuate Therapeutics (ACTU)?

A

The stock price for Actuate Therapeutics (NASDAQ: ACTU) is $1.29 last updated August 21, 2026 at 6:34 PM EDT.

Q

Does Actuate Therapeutics (ACTU) pay a dividend?

A

There are no upcoming dividends for Actuate Therapeutics.

Q

When is Actuate Therapeutics (NASDAQ:ACTU) reporting earnings?

A

Actuate Therapeutics does not have any upcoming earnings scheduled.

Q

Is Actuate Therapeutics (ACTU) going to split?

A

There is no upcoming split for Actuate Therapeutics.

Q

What sector and industry does Actuate Therapeutics (ACTU) operate in?

A

Actuate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.